Charcot-Marie-Tooth Disease Type I A – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Charcot-Marie-Tooth Disease Type I A – Drugs In Development, 2024 report and make more profitable business decisions.
Charcot–Marie–Tooth disease type 1A (CMT1A), the most frequent form of CMT, is caused by a 1.5 Mb duplication on the short arm of chromosome 17. CMT1 is characterized by muscle weakness and atrophy, which can lead to repeated ankle sprains, and changes in sensation (paresthesia), which can cause clumsiness. Symptoms of this form of CMT usually start in childhood and mostly affect the periphery of the body, particularly in the feet, lower part of the legs, hands, and forearms.
The Charcot-Marie-Tooth Disease Type I A drugs in development market research report provide comprehensive information on the therapeutics under development for Charcot-Marie-Tooth Disease Type I A, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Charcot-Marie-Tooth Disease Type I A and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Charcot-Marie-Tooth Disease Type I A | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 21 molecules, with 19 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Charcot-Marie-Tooth Disease Type I A therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Charcot-Marie-Tooth Disease Type I A pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Charcot-Marie-Tooth Disease Type I A treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Addex Therapeutics LtdAffectis Pharmaceuticals AG
Armatus Bio LLC
Augustine Therapeutics
Cedars-Sinai Medical Center
Encell Co Ltd
GeneNet Co Ltd
Helixmith Co Ltd
Imnewrun Bioscience Co Ltd
InFlectis BioScience SAS
Ionis Pharmaceuticals Inc
Lead Discovery Center GmbH
Nervosave Therapeutics
Novartis AG
Oryzon Genomics SA
Pharnext SA
Samsara Therapeutics Inc
Sanofi
Shape Therapeutics Inc
ToolGen Inc
UGISense AG
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Charcot-Marie-Tooth Disease Type I A reports